ACSL4 knockdown inhibits colorectal cancer progression through stimulating anti-tumor immunity

ACSL4 knockdown inhibits colorectal cancer progression through stimulating anti-tumor immunity

Background: Long-chain acyl-CoA synthetase 4 (ACSL4), a crucial modulator of ferroptosis, is associated with tumor progression, though its impact on colorectal cancer (CRC) immune dynamics is not fully understood.Methods: ACSL4 expression was analyzed in CRC tissues and correlated with patient progn...

Full description

Saved in:
Bibliographic Details
Main Authors: Yiming Liu, Xingyu Jiang, Dongquan Jing, Yanting Lin, Rui Gao, Qixiang Zhao, Huijuan Da, Yiming Ren, Qiuhua Cao, Ning Liu, Xiaoyun Han, Juan Du, Xinghua Gao
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
ACSL4
Tumor immunity
Colorectal cancer
RIG-I-MAVS
Type I Interferon
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558625000740
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Long-chain acyl-CoA synthetase 4 (ACSL4), a crucial modulator of ferroptosis, is associated with tumor progression, though its impact on colorectal cancer (CRC) immune dynamics is not fully understood.Methods: ACSL4 expression was analyzed in CRC tissues and correlated with patient prognosis. Effects of ACSL4 were evaluated in CRC cells in vitro and in subcutaneous and orthotopic CRC models. Flow cytometry and immunofluorescence were used to evaluate immune cell infiltration. RNA sequencing and RT-PCR were employed to identify ACSL4-regulated signaling pathways. The effect of ACSL4 silencing on PD-L1 blockade efficacy was also examined.Results: ACSL4 levels were markedly increased in CRC and linked to unfavorable patient outcomes. While ACSL4 knockdown had no direct effect on CRC cell proliferation, it significantly suppressed tumor growth in immunocompetent mice. ACSL4 depletion enhanced CD3⁺ and CD8⁺ T cell infiltration and upregulated chemokines (CXCL10, CXCL11) and antigen presentation genes (H2k1, TAP1, TAPBP). Transcriptomic analysis highlighted activation of the RIG-I-MAVS-driven type I interferon pathway. Co-culture assays demonstrated that ACSL4 knockdown promoted CD8⁺ T cell activation, and ACSL4-deficient tumors exhibited enhanced responsiveness to PD-L1 blockade.Conclusions: ACSL4 suppresses anti-tumor immunity in CRC by modulating the RIG-I-MAVS-IFN pathway, highlighting ACSL4 as a promising target for CRC immunotherapy.
ISSN:1476-5586

Similar Items